SI21745A - Polimorfi derivata 1-pirol-1-heptanojske kisline, intermediata za pripravo atorvastatina - Google Patents
Polimorfi derivata 1-pirol-1-heptanojske kisline, intermediata za pripravo atorvastatina Download PDFInfo
- Publication number
- SI21745A SI21745A SI200400112A SI200400112A SI21745A SI 21745 A SI21745 A SI 21745A SI 200400112 A SI200400112 A SI 200400112A SI 200400112 A SI200400112 A SI 200400112A SI 21745 A SI21745 A SI 21745A
- Authority
- SI
- Slovenia
- Prior art keywords
- phenyl
- methylethyl
- butyl ester
- tertiary butyl
- dihydroxy
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 34
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 title claims abstract description 33
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 title claims abstract description 30
- 229960005370 atorvastatin Drugs 0.000 title claims abstract description 30
- 238000000034 method Methods 0.000 claims abstract description 21
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 239000002253 acid Substances 0.000 claims abstract description 7
- OUCSEDFVYPBLLF-KAYWLYCHSA-N 5-(4-fluorophenyl)-1-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-n,4-diphenyl-2-propan-2-ylpyrrole-3-carboxamide Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@H]2OC(=O)C[C@H](O)C2)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 OUCSEDFVYPBLLF-KAYWLYCHSA-N 0.000 claims abstract description 6
- XUKUURHRXDUEBC-SVBPBHIXSA-N (3s,5s)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@H](O)C[C@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-SVBPBHIXSA-N 0.000 claims abstract description 4
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 65
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical group CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 claims description 59
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 45
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 35
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 34
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 30
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 20
- -1 phenylcarbamoyl Chemical group 0.000 claims description 17
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 9
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 claims description 8
- 239000011260 aqueous acid Substances 0.000 claims description 8
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 6
- 239000011877 solvent mixture Substances 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 4
- 238000009835 boiling Methods 0.000 claims description 3
- WSRKLYQAZKDXKA-UHFFFAOYSA-N 7-pyrrol-1-ylheptanoic acid Chemical compound OC(=O)CCCCCCN1C=CC=C1 WSRKLYQAZKDXKA-UHFFFAOYSA-N 0.000 claims description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 claims description 2
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 1
- BLGSOFJKVRONAD-UHFFFAOYSA-N heptanoic acid;1h-pyrrole Chemical compound C=1C=CNC=1.CCCCCCC(O)=O BLGSOFJKVRONAD-UHFFFAOYSA-N 0.000 claims 1
- 239000012450 pharmaceutical intermediate Substances 0.000 abstract description 2
- 239000000543 intermediate Substances 0.000 description 49
- 239000011541 reaction mixture Substances 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 7
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 5
- HKYSZTXMCCUHHV-UHFFFAOYSA-N 7-[2-phenyl-4-(phenylcarbamoyl)pyrrol-1-yl]heptanoic acid Chemical compound OC(=O)CCCCCCN1C=C(C(=O)NC=2C=CC=CC=2)C=C1C1=CC=CC=C1 HKYSZTXMCCUHHV-UHFFFAOYSA-N 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- HCPLPXQDAYFYCK-UHFFFAOYSA-N 7-[2-(phenylcarbamoyl)pyrrol-1-yl]heptanoic acid Chemical compound OC(=O)CCCCCCN1C=CC=C1C(=O)NC1=CC=CC=C1 HCPLPXQDAYFYCK-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- MXMUAWYZLLHAEA-UHFFFAOYSA-N 2-(1,3-dioxan-4-yl)acetic acid Chemical compound OC(=O)CC1CCOCO1 MXMUAWYZLLHAEA-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
- KJTLQQUUPVSXIM-ZCFIWIBFSA-M (R)-mevalonate Chemical compound OCC[C@](O)(C)CC([O-])=O KJTLQQUUPVSXIM-ZCFIWIBFSA-M 0.000 description 1
- YFMKJVDVNPLQFO-FQLXRVMXSA-N 2-[(4r,6r)-6-[2-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]ethyl]-2,2-dimethyl-1,3-dioxan-4-yl]acetic acid Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@H]2OC(C)(C)O[C@@H](CC(O)=O)C2)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 YFMKJVDVNPLQFO-FQLXRVMXSA-N 0.000 description 1
- 102100029077 3-hydroxy-3-methylglutaryl-coenzyme A reductase Human genes 0.000 description 1
- 101710158485 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 238000007330 Paal-Knorr Pyrrole synthesis reaction Methods 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002596 lactones Chemical group 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SI200400112A SI21745A (sl) | 2004-04-09 | 2004-04-09 | Polimorfi derivata 1-pirol-1-heptanojske kisline, intermediata za pripravo atorvastatina |
| SI200531002T SI1732886T1 (sl) | 2004-04-09 | 2005-04-08 | Polimorfi terc butil estra atorvastatina in uporaba kot intermediati za pripravo atorvastatina |
| HR20100217T HRP20100217T1 (hr) | 2004-04-09 | 2005-04-08 | POLIMORFI tert-BUTILNOG ESTERA ATORVASTATINA I NJIHOVA UPOTREBA KAO MEĐUPRODUKATA U DOBIVANJU ATORVASTATINA |
| CN200580012246XA CN1946687B (zh) | 2004-04-09 | 2005-04-08 | 阿托伐他汀叔丁基酯的多晶型物及其作为中间体在制备阿托伐他汀中的应用 |
| PCT/EP2005/003733 WO2005097742A1 (en) | 2004-04-09 | 2005-04-08 | Polymorphs of atorvastatin tert.-butylester and use as intermediates for the preparation of atorvastatin |
| PL05729986T PL1732886T3 (pl) | 2004-04-09 | 2005-04-08 | Odmiany polimorficzne estru tert.-butylowego atorwastatyny i ich zastosowanie jako związków pośrednich do wytwarzania atorwastatyny |
| CN2009101368132A CN101538238B (zh) | 2004-04-09 | 2005-04-08 | 阿托伐他汀叔丁基酯的多晶型物及其作为中间体在制备阿托伐他汀中的应用 |
| EP05729986A EP1732886B1 (en) | 2004-04-09 | 2005-04-08 | Polymorphs of atorvastatin tert.-butylester and use as intermediates for the preparation of atorvastatin |
| EA200601651A EA010166B1 (ru) | 2004-04-09 | 2005-04-08 | Полиморфные формы трет-бутилового эфира аторвастатина и их использование в качестве промежуточных соединений для получения аторвастатина |
| ES05729986T ES2339570T3 (es) | 2004-04-09 | 2005-04-08 | Polimorfos de ester terc-butilo de la atorvastatina y su utilizacion como intermediarios para la preparacion de la atorvastatina. |
| RSP-2010/0173A RS51259B (sr) | 2004-04-09 | 2005-04-08 | Polimorf atorvastatin tert.-butilestra i korišćenje intermediata za dobijanje atorvastatina |
| DK05729986.9T DK1732886T3 (da) | 2004-04-09 | 2005-04-08 | Polymorfer af atorvastasin-tert.-butylester og anvendelse som intermediære til fremstilling af atorvastatin |
| AT05729986T ATE459602T1 (de) | 2004-04-09 | 2005-04-08 | Polymorphe von atorvastatin-tert.-butylester und deren verwendung als zwischenprodukte für die herstellung von atorvastatin |
| DE602005019703T DE602005019703D1 (de) | 2004-04-09 | 2005-04-08 | Polymorphe von atorvastatin-tert.-butylester und deren verwendung als zwischenprodukte für die herstellung von atorvastatin |
| PT05729986T PT1732886E (pt) | 2004-04-09 | 2005-04-08 | Polimorfos de éster de tert-butilo de atorvastatina e utilização como intermediários para a preparação de atorvastatina |
| UAA200610957A UA86059C2 (ru) | 2004-04-09 | 2005-08-04 | Полиморфные формы трет-бутилового эфира аторвастатина и их использование как промежуточных соединений для получения аторвастатина |
| NO20065146A NO20065146L (no) | 2004-04-09 | 2006-11-08 | Polymorfer av atorvastatin tert.-butylester og anvendelse derav som mellomprodukter for fremstilling av atorvastatin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SI200400112A SI21745A (sl) | 2004-04-09 | 2004-04-09 | Polimorfi derivata 1-pirol-1-heptanojske kisline, intermediata za pripravo atorvastatina |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI21745A true SI21745A (sl) | 2005-10-31 |
Family
ID=34963800
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200400112A SI21745A (sl) | 2004-04-09 | 2004-04-09 | Polimorfi derivata 1-pirol-1-heptanojske kisline, intermediata za pripravo atorvastatina |
| SI200531002T SI1732886T1 (sl) | 2004-04-09 | 2005-04-08 | Polimorfi terc butil estra atorvastatina in uporaba kot intermediati za pripravo atorvastatina |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200531002T SI1732886T1 (sl) | 2004-04-09 | 2005-04-08 | Polimorfi terc butil estra atorvastatina in uporaba kot intermediati za pripravo atorvastatina |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1732886B1 (e) |
| CN (2) | CN101538238B (e) |
| AT (1) | ATE459602T1 (e) |
| DE (1) | DE602005019703D1 (e) |
| DK (1) | DK1732886T3 (e) |
| EA (1) | EA010166B1 (e) |
| ES (1) | ES2339570T3 (e) |
| HR (1) | HRP20100217T1 (e) |
| NO (1) | NO20065146L (e) |
| PL (1) | PL1732886T3 (e) |
| PT (1) | PT1732886E (e) |
| RS (1) | RS51259B (e) |
| SI (2) | SI21745A (e) |
| UA (1) | UA86059C2 (e) |
| WO (1) | WO2005097742A1 (e) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006313430B2 (en) * | 2005-11-08 | 2012-09-06 | Ranbaxy Laboratories Limited | Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt |
| US20100260851A1 (en) * | 2007-07-11 | 2010-10-14 | Actavis Group Ptc Ehf | Novel Polymorph of Atorvastatin Calcium and Use Thereof for the Preparation of Amorphous Atorvastatin Calcium |
| WO2009023260A2 (en) * | 2007-08-15 | 2009-02-19 | Teva Pharmaceutical Industries Ltd. | An improved process for synthesis of pyrrole derivative, an intermediate for atorvastatin |
| CN101560177B (zh) * | 2008-04-16 | 2012-10-03 | 北京万全阳光医学技术有限公司 | 一种阿托伐他汀钙的制备方法 |
| SI2413911T1 (sl) | 2009-03-31 | 2014-04-30 | Krka, D.D., Novo Mesto | Progresivna emulzijska kristalizacija |
| CN105693587A (zh) * | 2016-01-15 | 2016-06-22 | 安徽悦康凯悦制药有限公司 | 一种阿托伐他汀钙的生产工艺 |
| CN109280024A (zh) * | 2018-10-09 | 2019-01-29 | 河南师范大学 | 一种高纯度阿托伐他汀叔丁酯的制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| EP1341785B1 (en) * | 2000-11-16 | 2008-10-08 | Teva Pharmaceutical Industries Ltd. | Hydrolysis of r(r*,r*)-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- [(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide |
| US6476235B2 (en) * | 2001-01-09 | 2002-11-05 | Warner-Lambert Company | Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide |
| CN100430405C (zh) * | 2001-08-16 | 2008-11-05 | 特瓦制药工业有限公司 | 制备他汀类的钙盐形式的方法 |
-
2004
- 2004-04-09 SI SI200400112A patent/SI21745A/sl not_active IP Right Cessation
-
2005
- 2005-04-08 AT AT05729986T patent/ATE459602T1/de active
- 2005-04-08 CN CN2009101368132A patent/CN101538238B/zh not_active Expired - Fee Related
- 2005-04-08 CN CN200580012246XA patent/CN1946687B/zh not_active Expired - Fee Related
- 2005-04-08 WO PCT/EP2005/003733 patent/WO2005097742A1/en active Application Filing
- 2005-04-08 EA EA200601651A patent/EA010166B1/ru not_active IP Right Cessation
- 2005-04-08 DE DE602005019703T patent/DE602005019703D1/de not_active Expired - Lifetime
- 2005-04-08 PT PT05729986T patent/PT1732886E/pt unknown
- 2005-04-08 PL PL05729986T patent/PL1732886T3/pl unknown
- 2005-04-08 DK DK05729986.9T patent/DK1732886T3/da active
- 2005-04-08 RS RSP-2010/0173A patent/RS51259B/sr unknown
- 2005-04-08 EP EP05729986A patent/EP1732886B1/en not_active Expired - Lifetime
- 2005-04-08 HR HR20100217T patent/HRP20100217T1/hr unknown
- 2005-04-08 ES ES05729986T patent/ES2339570T3/es not_active Expired - Lifetime
- 2005-04-08 SI SI200531002T patent/SI1732886T1/sl unknown
- 2005-08-04 UA UAA200610957A patent/UA86059C2/ru unknown
-
2006
- 2006-11-08 NO NO20065146A patent/NO20065146L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| DE602005019703D1 (de) | 2010-04-15 |
| CN101538238B (zh) | 2012-08-29 |
| UA86059C2 (ru) | 2009-03-25 |
| EA200601651A1 (ru) | 2007-02-27 |
| RS51259B (sr) | 2010-12-31 |
| ES2339570T3 (es) | 2010-05-21 |
| ATE459602T1 (de) | 2010-03-15 |
| DK1732886T3 (da) | 2010-06-14 |
| HRP20100217T1 (hr) | 2010-05-31 |
| WO2005097742A1 (en) | 2005-10-20 |
| CN1946687A (zh) | 2007-04-11 |
| EA010166B1 (ru) | 2008-06-30 |
| SI1732886T1 (sl) | 2010-06-30 |
| EP1732886A1 (en) | 2006-12-20 |
| PT1732886E (pt) | 2010-03-12 |
| CN1946687B (zh) | 2011-09-28 |
| EP1732886B1 (en) | 2010-03-03 |
| CN101538238A (zh) | 2009-09-23 |
| NO20065146L (no) | 2006-11-08 |
| PL1732886T3 (pl) | 2010-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI94339B (fi) | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi | |
| KR100790766B1 (ko) | 아토르바스타틴의 결정 형태, 이의 제조방법 및 이를 포함하는 약제학적 조성물 | |
| KR100877165B1 (ko) | 수산화 칼슘을 이용한[Ｒ(Ｒ*,Ｒ*)]-2-(4-플루오로페닐)-β,δ-디하이드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카보닐]-1Ｈ-피롤-1-헵탄산 에스테르의 가수분해 | |
| RU2304139C2 (ru) | Кристаллические формы vi и vii кальциевой соли аторвастатина | |
| US20110190369A1 (en) | Substituted Pyrrole Derivatives and Their Use as HMG-CO Inhibitors | |
| JP2006503024A (ja) | Ｖｉ型アトルバスタチンカルシウムまたはその水和物 | |
| SI21745A (sl) | Polimorfi derivata 1-pirol-1-heptanojske kisline, intermediata za pripravo atorvastatina | |
| WO2007096751A1 (en) | Process for the preparation of atorvastatin calcium | |
| US20090099371A1 (en) | Process for the preparation of amorphous atorvastatin calcium salt | |
| US7074818B2 (en) | Crystalline forms VI and VII of Atorvastatin calcium | |
| WO2006092037A1 (en) | Process for producing atorvastatin hemicalcium | |
| US7361772B2 (en) | Process for the production of atorvastatin calcium | |
| JP2010516756A (ja) | アトルバスタチンのストロンチウム塩、及びこれを含む医薬組成物 | |
| US20040102511A1 (en) | Substituted pyrrole derivatives | |
| US20070149605A1 (en) | Substituted pyrrole derivatives as hmg-coa reductase inhibitors | |
| CA2679317A1 (en) | Novel crystal forms of pyrrolylheptanoic acid derivatives | |
| GB2424880A (en) | Crystalline forms of atorvastatin sodium, processes for their preparation and their use in inhibiting HMG-CoA reductase | |
| EP2373609A1 (en) | Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates | |
| WO2006067795A2 (en) | Novel polymorphic forms of atorvastatin lactone and process for preparing the same | |
| WO2006048888A1 (en) | Novel process for the preparation of amorphous atorvastatin calcium salt | |
| AU2011211338A1 (en) | Substituted pyrrole derivatives and their use as HMG-CO inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OO00 | Grant of patent |
Effective date: 20041118 |
|
| KO00 | Lapse of patent |
Effective date: 20071207 |